About Index Trending news
Analyze
Pricing
UniQure

UniQure

Work at UniQure? Add yourself to this profile

UniQure

uniQure is a world leader in the development of human gene based therapies for hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB.
Edit Profile
More info

Elsewhere

Also headquartered in Amsterdam

Royal Philips Royal Philips TomTom TomTom TNW TNW iCulture iCulture Startupbootcamp FinTech & CyberSecurity Startupbootcamp FinTech & CyberSecurity Emerce Emerce ING Group ING Group Tweakers Tweakers StartupJuncture StartupJuncture Adyen Adyen

Companies in the same industry

AgeneBio AgeneBio Bioheart Bioheart Entelos Entelos Morphogen-IX Morphogen-IX LAM Therapeutics LAM Therapeutics Emerus Hospital Partners Emerus Hospital Partners GLO Science GLO Science InSite Vision InSite Vision Molplex Molplex Laurantis Pharma Laurantis Pharma

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2
Add info
Latest funding
Debt financing
$20,000,000
Hercules Technology Growth Capital
Private equity
$58,000,000
Coller Capital
Employees

Team size

50+
Locations
HQ
Amsterdam, The Netherlands
Headquarters
Xconomy

UniQure to Yank Pioneering Gene Therapy From Market in Europe

Health Science
UniQure
UniQure
Xconomy

Struggling UniQure Cuts Gene Therapies, Jobs, in Big Restructuring

Health Strategy
UniQure
UniQure
The Motley Fool , Xconomy

Here's Why uniQure N.V.'s Stock Spiked Today --

UniQure
UniQure